Last updated: about 1 month ago
AstraZeneca's Camizestrant Breakthrough: A Game-Changer for HR-Positive Breast Cancer
Explore AstraZeneca's SERENA-6 trial results on camizestrant, showing significant PFS improvement for HR-positive breast cancer. Discover its market potential and safety profile.